Alunbrig

Active Ingredient(s): Brigatinib
FDA Approved: * April 28, 2017
Pharm Company: * ARIAD
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Alunbrig Overview

Brigatinib (INN,[1] previously known as AP26113, marketed as Alunbrig) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.[2] Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). In 28 April 2017, it was granted an Accelerated Approval from the US FDA for metastatic non-small cell lung cancer (NSCLC);[3][4] as a 2nd-line therapy for ALK-positive NSCL...

Read more Alunbrig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brigatinib

Recent Alunbrig Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Brigatinib
  • Tablet: 30mg, 90mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Alunbrig: (1 result)

Sorted by National Drug Code
  • 76189-113 Alunbrig 30 mg Oral Tablet, Coated by Ariad Pharmaceuticals Inc.

Other drugs which contain Brigatinib or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 23 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.